Vioxx Articles
USA needs new Rx drug approval system, says journal
24 January 2005
FDA panel rejects Merck & Co/J&J's application for OTC Mevacor
24 January 2005
Benefit of COX-2s vs conventional NSAIDs?
17 January 2005
Provalis sees 2004 sales grow 5%
17 January 2005
Canadian Medical Assoc slams regulators over approvals
10 January 2005
Stock Commentary - New York
10 January 2005
Editor's views on "Big Pharma" in 2004
10 January 2005
HIV/AIDS group urges ban on US DTC ads
10 January 2005
Further doubt cast over safety of Bextra
10 January 2005
Bayer and Stada hit by FDA warning on naproxen
10 January 2005
UK Ministry advice on COX-2s
10 January 2005
Stock Commentary - New York
20 December 2004
Merck & Co speeds up restructuring; 700 more jobs to go
20 December 2004
German post-Vioxx warning on COX-2s
20 December 2004
Merck & Co's first taste of life after Vioxx; earnings per share to take substantial hit
20 December 2004
Stock Commentary - Europe
13 December 2004
Stock Commentary - New York
22 November 2004
Editor's views on US HHS/FDA appointments; new UK regulatory agency
22 November 2004
Merck & Co's CEO called before US Senate
22 November 2004
Vioxx different to other COX-2s; study
22 November 2004
Study questions safety of Pfizer's Bextra
15 November 2004
Gloomy times for Merck & Co
15 November 2004
Pfizer defends Celebrex safety
15 November 2004
Stock Commentary - New York
8 November 2004
US approval of Merck & Co's Arcoxia on hold
8 November 2004
Vioxx withdrawal will not hurt COX-2s initially, says NOP survey
8 November 2004
EMA to review COX-2 inhibitors
1 November 2004
Stock Commentary - New York
25 October 2004
Merck & Co says study shows Arcoxia is safe
25 October 2004
US Sen questions Merck on FDA/Vioxx pact
25 October 2004
Disclose Rx AEs before licensing, says study
25 October 2004
Tokyo pharma stocks - week to October 4
11 October 2004
Stock Commentary - New York week to Oct 4
11 October 2004
Stock Commentary - Europe - week to Oct 4
11 October 2004
EMA to viewC OX-2s after Vioxx withdrawal
11 October 2004
Law firm investigates Merck & Co retirement plan
11 October 2004
Arthritis Rx ads "reach up to 75% of US patients"
4 October 2004
Merck & Co's Vioxx OKed for juvenile RA
20 September 2004
NicOx initiates HCT3012 vs rofecoxib study
20 September 2004
Vioxx study indicates heart risks
6 September 2004
MCO patients cannot sue: US Supreme Court rules
28 June 2004
Promising Ph II results for NicOx' HCT 3012
21 June 2004
Merck & Co's Vioxx gets FDA OK for new use
12 April 2004
Merck & Co updates on Vioxx-R and Arcoxia filings
8 March 2004
Merck & Co 4th-qtr in line with estimates; net income down 23%
2 February 2004
Teva set to contest Fosamax court ruling
8 September 2003
Pfizer's Bextra gives lower medical costs
30 June 2003
Stock Commentary - New York
30 June 2003
Pfizer's Bextra gives lower medical costs
30 June 2003
Merck & Co in $175M Spanish investment
30 June 2003
ProEthic transdermal ketoprofen deal
14 April 2003
MisRxing "could cost Australia A$1B/year"
17 March 2003
Bany to delay rofecoxib filing in Japan
3 March 2003
First launch, in Canada, for AstraZeneca's superstatin Crestor
24 February 2003
Update: Pharmacia's earnings match forecasts in 2002
24 February 2003
Pharmacia's earnings match forecasts in 2002
24 February 2003
Effect of Merck & Co Banyu buy assessed
27 January 2003
10 most effective US DTC television ads
5 August 2002
Merck & Co reconfirms 2002 guidance
17 June 2002
Merck & Co will refile Arcoxia NDA in 2003
17 June 2002
Merck & Co will refile Arcoxia NDA in 2003
17 June 2002
FDA clears Celebrex label change
17 June 2002
Banyu says Proscar still on file in Japan
3 June 2002
Stock Commentary - New York
25 March 2002
Tokyo pharma stocks - week to March 18
25 March 2002
US insurers requiring prior OK for COX-2s
25 March 2002
Merck & Co claims victory in COX-2 patent dispute
11 March 2002
UK NICE guidance on COX-2s "may be short-sighted"
25 February 2002
Stock Commentary - New York
4 February 2002
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
